[HTML][HTML] Phase 1 trial of Bi-shRNA STMN1 BIV in refractory cancer
M Barve, Z Wang, P Kumar, CM Jay, X Luo, C Bedell… - Molecular Therapy, 2015 - cell.com
Stathmin1 (STMN1) is a microtubule modulator that is expressed in multiple cancers and
correlates with poor survival. We previously demonstrated in vivo safety of bifunctional (bi) …
correlates with poor survival. We previously demonstrated in vivo safety of bifunctional (bi) …
[HTML][HTML] Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
M Barve, Z Wang, P Kumar, CM Jay, X Luo… - Molecular …, 2015 - ncbi.nlm.nih.gov
Abstract Stathmin1 (STMN1) is a microtubule modulator that is expressed in multiple
cancers and correlates with poor survival. We previously demonstrated in vivo safety of …
cancers and correlates with poor survival. We previously demonstrated in vivo safety of …
[HTML][HTML] Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
M Barve, Z Wang, P Kumar, CM Jay, X Luo, C Bedell… - Molecular Therapy, 2015 - Elsevier
Stathmin1 (STMN1) is a microtubule modulator that is expressed in multiple cancers and
correlates with poor survival. We previously demonstrated in vivo safety of bifunctional (bi) …
correlates with poor survival. We previously demonstrated in vivo safety of bifunctional (bi) …
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
M Barve, Z Wang, P Kumar, CM Jay, X Luo… - … Therapy: the Journal …, 2015 - europepmc.org
Abstract Stathmin1 (STMN1) is a microtubule modulator that is expressed in multiple
cancers and correlates with poor survival. We previously demonstrated in vivo safety of …
cancers and correlates with poor survival. We previously demonstrated in vivo safety of …
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
M Barve, Z Wang, P Kumar, CM Jay… - … therapy: the journal …, 2015 - pubmed.ncbi.nlm.nih.gov
Stathmin1 (STMN1) is a microtubule modulator that is expressed in multiple cancers and
correlates with poor survival. We previously demonstrated in vivo safety of bifunctional (bi) …
correlates with poor survival. We previously demonstrated in vivo safety of bifunctional (bi) …
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
M Barve, Z Wang, P Kumar, CM Jay, X Luo… - Molecular …, 2015 - search.proquest.com
Abstract Stathmin1 (STMN1) is a microtubule modulator that is expressed in multiple
cancers and correlates with poor survival. We previously demonstrated in vivo safety of …
cancers and correlates with poor survival. We previously demonstrated in vivo safety of …
[PDF][PDF] Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
M Barve, Z Wang, P Kumar… - Molecular …, 2015 - mary-crowley-web.s3.amazonaws …
Stathmin 1 (STMN1), a protumorigenic protein, is a critical intermediate during signal
transduction in modulation and control of microtubule depolymerization and interphase …
transduction in modulation and control of microtubule depolymerization and interphase …
[PDF][PDF] Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
M Barve, Z Wang, P Kumar, CM Jay, X Luo… - Molecular …, 2015 - marycrowley.org
Stathmin 1 (STMN1), a protumorigenic protein, is a critical intermediate during signal
transduction in modulation and control of microtubule depolymerization and interphase …
transduction in modulation and control of microtubule depolymerization and interphase …
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
M Barve, Z Wang, P Kumar, CM Jay, X Luo… - Molecular …, 2015 - search.ebscohost.com
Abstract Stathmin1 (STMN1) is a microtubule modulator that is expressed in multiple
cancers and correlates with poor survival. We previously demonstrated in vivo safety of …
cancers and correlates with poor survival. We previously demonstrated in vivo safety of …